1 week Ago By Defense World Staff
Sei Investments Co. increased its holdings in CareDx, Inc (NASDAQ:CDNA – Free Report) by 13.6% in the 4th quarter, according to its most recent 13F filing with the SEC.
The firm owned 47,105 shares of the company’s stock after buying an additional 5,649 shares during the period. Sei Investments Co. owned about 0.
09% of CareDx worth $1,009,000 as of its most recent filing with the SEC. A number of other institutional investors have also modified their holdings of the business. Teacher Retirement System of Texas boosted its stake in CareDx by 19.
6% in the fourth quarter. Teacher Retirement System of Texas now owns 14,878 shares of the company’s stock valued at $319,000 after acquiring an additional 2,442 shares during the period. Intech Investment Management LLC lifted its holdings in shares of CareDx by 34.
9% in the 4th quarter. Intech Investment Management LLC now owns 19,395 shares of the company’s stock worth $415,000 after purchasing an additional 5,015 shares during the last quarter. Royce & Associates LP boosted its position in CareDx by 23.
1% during the 4th quarter. Royce & Associates LP now owns 484,286 shares of the company’s stock valued at $10,369,000 after purchasing an additional 91,000 shares during the period. Swiss National Bank grew its stake in CareDx by 1.
9% during the 4th quarter. Swiss National Bank now owns 98,600 shares of the company’s stock worth $2,111,000 after buying an additional 1,800 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd.
increased its position in CareDx by 25.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd.
now owns 875,197 shares of the company’s stock worth $18,738,000 after buying an additional 178,304 shares during the period. CareDx Stock Up 2.5 %CDNA stock opened at $17.
72 on Tuesday. The company has a 50-day simple moving average of $20.80 and a 200 day simple moving average of $23.
10. The company has a market capitalization of $982.15 million, a P/E ratio of -6.
56 and a beta of 2.18. CareDx, Inc has a fifty-two week low of $7.
42 and a fifty-two week high of $34.84. CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th.
The company reported $1.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $1.
46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.
70%. The company had revenue of $86.58 million during the quarter, compared to analyst estimates of $84.
56 million. Equities analysts anticipate that CareDx, Inc will post -0.9 EPS for the current year.
Wall Street Analyst Weigh InSeveral equities analysts have recently issued reports on the stock. Stephens reissued an “overweight” rating and set a $40.00 price target on shares of CareDx in a report on Thursday, February 27th.
HC Wainwright cut their price objective on shares of CareDx from $26.00 to $25.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd.
Wells Fargo & Company upgraded shares of CareDx from an “underweight” rating to an “equal weight” rating and decreased their target price for the stock from $28.00 to $24.00 in a research report on Wednesday, January 15th.
Finally, StockNews.com raised CareDx from a “hold” rating to a “buy” rating in a report on Wednesday, February 26th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company.
According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.83.
View Our Latest Stock Report on CareDxCareDx Profile (Free Report)CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.Recommended StoriesFive stocks we like better than CareDxInvesting In Preferred Stock vs.
Common StockOptions Activity Points to More Volatility for Palantir StockUpcoming IPO Stock Lockup Period, ExplainedNVIDIA Stock: Oversold, Undervalued — How Low Can It Go?What is the Nasdaq? Complete Overview with HistoryMicroStrategy Sees Insider Buy-Sell Action in Q1.
